Zopiclone MarketSize and Trends

Global Zopiclone Market Drivers

Leading manufacturers are focusing on manufacturing of zopiclone, which is expected to aid in growth of the global zopiclone market. For instance, several players have launched generics for the brand Lunesta (zopiclone) after its patent expiration in the year 2014. For instance, manufacturers such as Mylan and Dr. Reddys Laboratories have launched generic lunesta (cheaper than brand name drug) in the U.S. in 2014. Moreover, according to the article published by the non-profit organization, Best Practice Advocacy Centre New Zealand (bpac^nz), October 2018, New Zealand is the largest user of prescribed hypnotic medicine, and zopiclone is prescribed for the treatment of insomnia.

Moreover, according to the same source, the following figures show the statistics for number of patients suffering from insomnia per 1,000 population in New Zealand for the year 2017 - 3.2 patients (under 25 years), 18.9 patients (26 – 35 years), 30.4 patients (36 – 45 years), 45.6 patients (46 – 55 years), 60.7 patients (56 – 65 years), and 86.9 patients (over 65 years) and around similar numbers have been recorded for the years, 2016, 2015, 2014, and 2013.

Prevalence of insomnia in Asia Pacific region is found to be lower than in Europe and North America. According to National Center for Biotechnology Information (NCBI), 2019, geriatric population suffers from insomnia and others including psychiatric disorders such as depression, anxiety, and post-traumatic stress disorder. According to the same source, comorbid health issues such as restless leg syndrome, gastroesophageal reflux disease (GERD), respiratory disorders and chronic pain, and alcohol or substance abuse can also contribute to insomnia.